About This Fund
Developer of gene-based therapies for rare diseases. The first commercialized product is Naglazyme for Mucopolysaccharidosis VI. The lead program is gene therapy with hepatocyte growth factor (HGF) plasmid to improve blood circulation by regenerating blood vessels, for the treatment of critical limb ischemia.
Investment Focus
Sectors
Stages
Check Size
$150K average per project; fund size $1M-$3M
Geography
What They Look For
Quebec and Canada-based tech startups; innovative companies with traction from experienced investors; accredited investors only for fund participation
Preparing to pitch AnGes?
CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.
Analyze My Deck →